None of us shareholders would agree to sell to a BP at these levels. This product, and thus this company, is worth no less than $15/share to me. That would be the minimum value I would say yes to when voting my shares regarding a buyout.
Forget about GSK. After what's happened, I doubt Thero would sell the company to them at anything other than a ridiculously high price. Rather, let's beat em on sales!
Left a big "hang man" on the daily candlestick chart. Technically speaking it looks like the next stop is $44 per share . If they fail to pick up a potential block buster like Vascepa to make up for losses to generic Lovaza they may drop into the $30's. The fact they haven't bought AMRN is evidence of pisz poor mgt. There is no other company in a position to exploded out of the gates with Vascepa. They could have converted every L patient and more. Dumb dumb dumb
Surely you jest. Ihub does the same thing. You can bash all you want there but if someone is an idiot you cannot call them out on it there as you can here.
He was saying 30 to drive the price while he sold, he was asking both BMS and AZ for $7.5 per share, that's why the current management and JZ may sit behind bars for a while when this goes to trial. For JZ, he has a big mouth so tracking his events isn't too difficult. Also, his buying all the new homes cant shield the settlement folks.
It's bankrupt within 2 years. Highly leveraged company with mountains of debt. And still, they won't sell the company. The value of the company decreases daily as they continue to lose cash. More debt than cash right now, with cash decreasing.
Can you even fathom "not a penny under $30!" was the actual anthem fairly recently? Mind boggling stuff.
You've failed to disclose that the statistically significant results shown in the JELIS study were conducted in a group with fairly low levels of triglycerides around 150 mg/dL I believe, and who already had high levels of omega 3 to 9 ratios due to diet. The improvements already shown in inflammatory and lipid markers in western populations along with the significantly higher levels of triglycerides will lead to significant reductions in adverse CV events in REDUCE-IT populations. To say otherwise is to be incapable of basic understanding of the key issues of high inflammation and high blood lipid levels being responsible for CV disease burden.
The article sure is a great primer for everyone, I like that the author is currently adding shares. I am also adding from time to time. Frankly, I'm surprised this company hasn't been bought by BP at these rates. If that happens, I'll lose money.
FDA has to much power and I hope AMRN does question their First Amendment rights. Perhaps, a good law firm could uncover a payoff by BP.
The vibrant discussion community migrated to ST and IH ub. Yahoo is a ghost town because they refuse to police the site, and in fact seem to have a revenue stream from the entities that pay bashers.
If you are a real investor, what do you like? I know you hate AMRN. We all know that. Buffett once said stocks can make you look stupid for a very long time before you are proven right. So suck it. Rick Harrison told me to say "waddup" to you when I was pawning my left nut. I know we all look like donkeys for owning AMRN, so why don't you tell us what we should own. You are a biopharma stock guru, are you not?
good to see you keeping it real on this board it been a while... the bashers are long gone today